ScholarGate
助手

方法对比

并排查看您选择的方法;存在差异的行会高亮显示。

UCLA前列腺癌指数:前列腺癌特异性生活质量功能评估×EORTC QLQ-LC13:肺癌生活质量×
领域肿瘤学肿瘤学
方法族Process / pipelineProcess / pipeline
起源年份19981994
提出者Litwin, M. S., et al.Bergman, B., et al. (EORTC Quality of Life Group)
类型Self-report questionnaireSelf-report questionnaire
开创性文献Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. DOI ↗Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642. DOI ↗
别名UCLA PCI, PCIQLQ-LC13
相关55
摘要The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes.The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials.
ScholarGate数据集
  1. v1
  2. 2 来源
  3. PUBLISHED
  1. v1
  2. 2 来源
  3. PUBLISHED

前往搜索 下载幻灯片

ScholarGate方法对比: UCLA Prostate Cancer Index · EORTC QLQ-LC13. 于 2026-06-20 检索自 https://scholargate.app/zh/compare